Mankind Pharma Ltd

BSE : MANKIND22 Jan 2025

Pharmaceuticals

₹

-48.30 (-1.88%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Mankind Pharma Ltd

Mankind Pharma Ltd

Pharmaceuticals

BSE : MANKIND22 Jan 2025

₹

-48.30 (-1.88%)

OverviewFundamentals

Corporate action

Peer comparison

Cash flow

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
13-Jan-2025	BC	Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the unaudited standalone and consolidated fi	23-Jan-2025
14-Jan-2025	BC	Intimation of Record Date for redemption of Commercial Paper issued by the Company	15-Jan-2025
08-Jan-2025	BC	Outcome of the Board Meeting held today i.e. January 8, 2025	09-Jan-2025
08-Jan-2025	BC	Outcome of the Board Meeting held today i.e. January 8, 2025.	08-Jan-2025
23-Dec-2024	BC	Trading members of the Exchange are hereby informed that the under mentioned securities of Mankind Pharma Limited (Scrip Code :543904, ISIN No. INE634S01028) are listed and admitted for trading on t	24-Dec-2024

No Rights has been declared by MANKIND

Book Closure

Record Date	Split Date	Purpose
23-Jan-2025	-	Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the unaudited standalone and consolidated fi
15-Jan-2025	-	Intimation of Record Date for redemption of Commercial Paper issued by the Company
09-Jan-2025	-	Outcome of the Board Meeting held today i.e. January 8, 2025
08-Jan-2025	-	Outcome of the Board Meeting held today i.e. January 8, 2025.
24-Dec-2024	-	Trading members of the Exchange are hereby informed that the under mentioned securities of Mankind Pharma Limited (Scrip Code :543904, ISIN No. INE634S01028) are listed and admitted for trading on t

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Mankind Pharma Ltd ₹2,515.05(-48.30/-1.88%)	2,515.05	-48.30	103,762.64	17.46	51.77	7.53
Bliss GVS Pharma Ltd ₹165.70(+2.80/1.72%)	165.70	+2.80	1,745.92	35.21	21.60	1.70
Amrutanjan Health Care Ltd ₹690.45(+11.05/1.63%)	690.45	+11.05	1,996.13	16.55	42.00	6.70
Astrazeneca Pharma India Ltd ₹6,967.40(+186.80/2.75%)	6,967.40	+186.80	17,418.50	10.43	135.32	25.64
Abbott India Ltd ₹27,745.95(+105.95/0.38%)	27,745.95	+105.95	58,960.14	9.02	45.90	16.74
Ambalal Sarabhai Enterprises Ltd ₹49.16(-0.47/-0.95%)	49.16	-0.47	376.73	2.61	42.75	8.36

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Cash and Cash Equivalents at Beginning of the year	134.13	86.17	46.36	77.50	72.48
Net Cash from Operating Activities	1982.97	1798.99	821.44	983.38	959.61
Net Cash Used In Investing Activities	-1919.22	-1040.61	-1360.27	-1127.16	-395.68
Net Cash Used In Financing Activities	-8.68	-710.41	578.63	88.87	-558.91
Net Inc./Dec In Cash And Cash Equivalents	55.07	47.96	39.81	-54.91	5.02
Cash And Cash Equivalents At End Of The Year	189.20	134.13	86.17	22.58	77.50

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

72.71%

FII Shareholding

13.34%

DII Shareholding

11.06%

Public Shareholding

2.90%

**Promoter pledged shareholding 72.71%

About Mankind Pharma Ltd

Mankind Pharma Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 103762.64 crores. It has reported a sales of Rs. 2529.74 crores and a net profit of Rs. 634.43 crores for the quarter ended December 2018. The company management includes RAMESH CHAND JUNEJA, RAMESH CHAND JUNEJA,RAJEEV JUNEJA,SHEETAL ARORA,TILOKCHAND PUNAMCHAND OSTWAL,Bharat Anand,SATISH KUMAR SHARMA,Vivek Kalra,Vijaya Sampath,Hitesh Kumar Jain (Mankind Pharma Ltd) among others.

Chairman

RAMESH CHAND JUNEJA

Registered office

208 Okhla Industrial Estate,Phase-III,New Delhi,New Delhi,110020

FAX :

Background

Incorporation Year1991

Face Value₹1

Market Lot1